AstraZeneca stock slips as weak momentum limits further upside

Traders Union
All News
Financial News
AstraZeneca slides 1.10% to GBX14938.00

Highlights

AstraZeneca's tozorakimab met key endpoints in Phase III for COPD, showing reduced exacerbations in both former and current smokers.
Ongoing progress in the oncology pipeline includes further Phase III trial readouts for datopotamab deruxtecan and Lynparza combinations, with a target of 50 novel oncology molecules by 2030.
Technicals signal a bullish longer-term structure above immediate support at GBX 14,463, with expected consolidation between GBX 14,500 and GBX 15,100 amid overbought short-term conditions.

Drug pipeline momentum offsets selling pressure amid successful trial updates

AstraZeneca reported that its experimental biologic drug tozorakimab met primary goals in the Phase III MIRANDA trial for chronic obstructive pulmonary disease, demonstrating reduced exacerbations in both former and current smokers. The company is also advancing its oncology pipeline with ongoing Phase III readouts for therapies such as datopotamab deruxtecan in lung cancer and updates regarding Lynparza combinations. Progress toward the target of 50 novel oncology molecules by 2030 was mentioned, though price action has remained under broader selling pressure.

Technical overbought signals as weak momentum meets support above key levels

The GBX 14,938 price sits above the SMA-20 at GBX 14,641.50, SMA-50 at GBX 14,740.88, and SMA-200 at GBX 13,054.48. The Ichimoku Kijun on the daily chart is at GBX 14,463, serving as immediate support. MACD remains positive on both daily and weekly timeframes, but the daily ADX reads only 15.26, indicating weak trend momentum. RSI is neutral at 57.1 and Stoch RSI at 46.3; Bull/Bear Power (BBP) is highly overbought at 208.62, while oscillators such as CCI and the Awesome Oscillator are neutral. The price is trading in the lower third of today's range.

Upside probability rises with weekly indicator alignment and range consolidation

For the coming week, the expected trading range is GBX 14,500 to GBX 15,100, representing a typical volatility band relative to current levels. The probability of an upward move is assessed as very high, supported by indicator alignment on the weekly chart. Baseline expectations are for the price to consolidate within this band. A move above GBX 15,100 would increase the likelihood of further short-term gains, while a drop below immediate support at GBX 14,463 could open the way to the next support near GBX 14,100.

Viktoras Karapetjanc, Traders Union expert, sees AstraZeneca’s strong fundamentals and robust clinical pipeline as key drivers for resilience despite recent price pressure. He believes the recent positive news in respiratory and oncology projects bolsters long-term sentiment. With price holding above major moving averages and bullish weekly indicators, he maintains a constructive outlook for consolidation and potential gains. "I expect strong institutional support to keep AstraZeneca above GBX 14,463 and see clear conditions for an upward move if price breaks GBX 15,100."

Earlier, analysts noted that AstraZeneca's strong technical setup and portfolio expansion pointed to continued bullish potential. The latest clinical milestones and resilient trend signals reinforce this outlook, with a sustained move above GBX 15,100 likely to trigger further upside momentum in the near term.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.